1. 1) United Nations Office on Drugs and Crime. “Fentanyl and its analogues—50 years on. Global Smart Update, Vol.17, 2017.”: ‹http://www.unodc.org/documents/scientific/Global_SMART_Update_17_web.pdf›, cited 10 August, 2018.
2. 2) McIntyre IM, Trochta A, Gary RD, Wright J, Mena O. An acute butyr-fentanyl fatality: a case report with postmortem concentrations. J. Anal. Toxicol., 40, 162–166 (2016).
3. 3) Higashikawa Y, Suzuki S. Studies on 1-(2-phenethyl)-4-(N-propionylanilino)piperidine (fentanyl) and its related compounds. VI. Structure–analgesic activity relationship for fentanyl, methyl-substituted fentanyls and other analogues. Forensic Toxicol., 26, 1–5 (2008).
4. 4) Drug Enforcement Administration, Department of Justice. Schedules of controlled substances: temporary placement of butyryl fentanyl and beta-hydroxythiofentanyl into Schedule I. Final order. Fed. Regist., 81, 29492–29496 (2016).
5. 5) Steuer AE, Williner E, Staeheli SN, Kraemer T. Studies on the metabolism of the fentanyl-derived designer drug butyrfentanyl in human in vitro liver preparations and authentic human samples using liquid chromatography-high resolution-mass spectrometry (LC-HR-MS). Drug Test. Anal., 9, 1085–1092 (2017).